Plus Communication company information, Employees & Contact Information

Reviews: New Primal’s Spin On Rotisserie; Plus, AL’s Real Goods, NOVOS Longevity Bars Nosh.com

The MLB playoff picture is set! Who clinched, plus current matchups and schedule ESPN

AL East race is heating up. Plus: All-Star starter surprises The New York Times

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial The Lancet

Hauling Al: Teague is at 380-Plus and Looking for Four HOT ROD Network

Object fire protection systems for industrial equipment and machinery Siemens

Budget-friendly grocery chain cutting prices up to 33% on 400-plus items AL.com

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial Nature

Game 158: Red Sox at Blue Jays lineups, plus the magic number for Boston The Boston Globe

Al Jazeera Allegedly Using Bots to Spread Propaganda While Skirting U.S. Law Foundation for Defense of Democracies

A surprise pick to win the AL East, plus Alex Verdugo finally comes off the board The New York Times

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer The New England Journal of Medicine

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial | Journal of Clinical Oncology ASCO Publications

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial Nature

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer The New England Journal of Medicine

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year E ASCO Publications

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial Nature

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma The New England Journal of Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 The New England Journal of Medicine

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma The New England Journal of Medicine

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma The New England Journal of Medicine

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer The New England Journal of Medicine

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia Nature

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Nature

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial Nature

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer The New England Journal of Medicine

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine The New England Journal of Medicine

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer The New England Journal of Medicine

Music Reviews: An ‘Ultimate’ Edition of John Lennon’s First Major Solo Album, Plus Al Stewart’s ‘Year of the Cat’ Americana Highways

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C The New England Journal of Medicine

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations The New England Journal of Medicine

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer The New England Journal of Medicine

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial Nature

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma The New England Journal of Medicine

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer The New England Journal of Medicine

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer The New England Journal of Medicine

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial Nature

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma ASCO Publications

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions The New England Journal of Medicine

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer The New England Journal of Medicine

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial Nature

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study | Journal of Clinical Oncology ASCO Publications

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma The New England Journal of Medicine

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer The New England Journal of Medicine

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis The New England Journal of Medicine

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma The New England Journal of Medicine

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients Nature

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer Nature

CMOS plus stochastic nanomagnets enabling heterogeneous computers for probabilistic inference and learning Nature

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma The New England Journal of Medicine

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma The New England Journal of Medicine

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome The New England Journal of Medicine

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma The New England Journal of Medicine

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer The New England Journal of Medicine

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer Nature

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma The New England Journal of Medicine

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma The New England Journal of Medicine

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV The New England Journal of Medicine

Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial The Lancet

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation The New England Journal of Medicine

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden The New England Journal of Medicine

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma The New England Journal of Medicine

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA | Leukemia Nature

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma The New England Journal of Medicine

Brady Cook injury status change, plus Alabama football availability report before Missouri AL.com

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma The New England Journal of Medicine

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer The New England Journal of Medicine

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer The New England Journal of Medicine

Hydrocortisone plus Fludrocortisone for Adults with Septic Shock The New England Journal of Medicine

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer The New England Journal of Medicine

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2 -amplified metastatic colorectal cancer: a phase 2 trial Nature

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma The New England Journal of Medicine

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma The New England Journal of Medicine

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer The New England Journal of Medicine

The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial Nature

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial The Lancet

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma The New England Journal of Medicine

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia The New England Journal of Medicine

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer The New England Journal of Medicine

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma The New England Journal of Medicine

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer The New England Journal of Medicine

Estrogen plus Progestin and the Risk of Coronary Heart Disease The New England Journal of Medicine

Nivolumab plus Ipilimumab in Advanced Melanoma The New England Journal of Medicine

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma The New England Journal of Medicine

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions The New England Journal of Medicine

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer The New England Journal of Medicine

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma The New England Journal of Medicine

South Alabama capital campaign raises $160.9 million, exceeds goal by $10 million-plus AL.com

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer The New England Journal of Medicine

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer The New England Journal of Medicine

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma The New England Journal of Medicine

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection The New England Journal of Medicine

Music Reviews: Eric Andersen’s ‘The Writer Series’ and ‘Woodstock Under the Stars,’ Plus Al Stewart and Kelly Finnigan Americana Highways

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer The New England Journal of Medicine

Alabama white barbeque sauce plus nachos equals yes AL.com

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a rando The Lancet

Pyrolysis Study of Different Fruit Wastes Using an Aspen Plus Model Frontiers

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma The New England Journal of Medicine

I tried Logitech's new aluminum G502 X - the mouse it doesn't want you to own PCGamesN

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis The New England Journal of Medicine